NASDAQ:PYPD PolyPid Q3 2026 Earnings Date & Estimates $4.89 +0.02 (+0.31%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more. PolyPid is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from PolyPid in Q3 2026PolyPid is expected to post earnings of $0.25 per share on revenue of $15.00 million. In the same quarter a year earlier PolyPid reported -$0.37 per share. PolyPid last reported on August 12, 2026, posting -$0.35 per share and beating the -$0.3775 consensus estimate. PolyPid has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.25Expected Revenue$15.00 millionPrior-Year EPS-$0.37Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.35 (Beat by +$0.0275)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report PolyPid Q3 2026 Earnings FAQ When does PolyPid report Q3 2026 earnings? PolyPid (NASDAQ:PYPD) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is PolyPid's Q3 2026 earnings call? PolyPid's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for PolyPid? Analysts expect PolyPid to post earnings of $0.25 per share for Q3 2026. How much revenue is PolyPid expected to report? The consensus revenue estimate for PolyPid is $15.00 million for Q3 2026. PolyPid Earnings HeadlinesWhat PolyPid's Bold Moves in Europe Could Mean for D-PLEX₁₀₀'s Global Potential (NASDAQ: PYPD)October 9, 2026 | markets.businessinsider.comPolyPid Ltd.: PolyPid Regains European Commercialization Rights for D-PLEX100, Expanding Global Commercialization OpportunitiesOctober 1, 2026 | finanznachrichten.deRent out your stocks?If you owned a rental house, you would collect rent while you waited for it to rise in value. A covered call lets you do something similar with stocks you already own. Own at least 100 shares and you can get paid cash today for agreeing to sell them at a higher price later. That cash is yours to keep no matter what happens next. Bill Poulos breaks it down in The Retirement Paycheck Playbook, normally $29.97, free today.October 14 at 1:00 AM | Profits Run (Ad)European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀October 1, 2026 | markets.businessinsider.comEuropean Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀October 1, 2026 | globenewswire.comPolyPid Announces Termination of ADVANZ PHARMA Europe Agreement for D-PLEX100, Regains European RightsOctober 1, 2026 | quiverquant.comQSee More PolyPid Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PolyPid? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PolyPid and other key companies, straight to your email. Email Address About PolyPidPolyPid (NASDAQ:PYPD) is an Israel-based clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at the site of treatment. Its technology is intended to improve therapeutic exposure while limiting systemic side effects. The company’s lead product candidate, D-PLEX100, is an investigational formulation of doxycycline designed for prolonged release at surgical sites. PolyPid has studied D-PLEX100 as a potential treatment to help prevent surgical-site infections, including infections associated with abdominal and colorectal procedures. The product is based on the company’s proprietary PLEX polymer-lipid delivery matrix. PolyPid was founded in 2008 and is headquartered in Israel. The company has conducted clinical development activities in the United States, Israel and other countries, with a focus on advancing locally delivered therapies for surgical and other medical applications.View PolyPid ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
